Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL303558 | 0.98 | PTGS2 (0.52) | PTGS2CALM1SMN1; SMN2CA12CA1 | |
| Leucine SCHEMBL636008 | 0.82 | LARS1 (0.43) | PTGS2CALM1L3MBTL1POLBKDM4E | |
| SCHEMBL23509449 | 0.82 | CALM1 (0.47) | CALM1SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL23509400 | 0.81 | PTGS2 (0.50) | PTGS2SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL12844009 | 0.80 | CALM1 (0.61) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL28148450 | 0.78 | ALDH1A1 (0.47) | CALM1SMN1; SMN2CA2L3MBTL1KDM4E | |
| SCHEMBL3125186 | 0.78 | CALM1 (0.58) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL7089061 | 0.78 | CALM1 (0.58) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL1223578 | 0.78 | KDM4E (0.77) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL14308534 | 0.77 | CALM1 (0.54) | CALM1SMN1; SMN2CA2CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606907-A1 | RACEMIC BETA-AMINOSULFONE COMPOUNDS | Quimica Sintetica, S.A. (ES) | 2020-02-12 | — | — | EP | claimed |
| EP-3606908-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | Quimica Sintetica, S.A. (ES) | 2020-02-12 | — | — | EP | claimed |
| WO-2018184933-A1 | RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIMICA SINTETICA, S. A. (ES) | 2018-10-11 | — | — | WO | claimed |
| WO-2018184936-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIMICA SINTETICA, S. A. (ES) | 2018-10-11 | — | — | WO | claimed |
| WO-2023116707-A1 | PREPARATION FOR THIOPHENE DERIVATIVE | 赣州和美药业有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2022132603-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-11149003-B2 | Resolution of racemic beta-aminosulfone compounds | QUIMICA SINTETICA, S.A. (ES) | 2021-10-19 | — | — | US | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20200199072-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIMICA SINTETICA, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3606908-B1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIM SINTETICA S A (ES) | 2020-06-17 | — | — | EP | disclosed |
| EP-3606907-A1 | RACEMIC BETA-AMINOSULFONE COMPOUNDS | Quimica Sintetica, S.A. (ES) | 2020-02-12 | — | — | EP | disclosed |
| EP-3606908-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | Quimica Sintetica, S.A. (ES) | 2020-02-12 | — | — | EP | disclosed |
| US-9944599-B2 | Processes for the preparation of beta-aminosulfone compounds | LEK PHARMACEUTICALS (SI) | 2018-04-17 | — | — | US | disclosed |
| WO-2017179065-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017175087-A1 | PROCESS FOR PREPARATION OF AMORPHOUS APREMILAST | INTAS PHARMACEUTICALS LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017105263-A1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL AGENT | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174627-A1 | Processes For The Preparation Of Beta-Aminosulfone Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2017-06-22 | — | — | US | disclosed |
| WO-2017046319-A1 | A SYNTHETIC PATHWAY TOWARDS APREMILAST | LEK PHARMACEUTICALS D.D. (SI) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016199031-A1 | PROCESS FOR PREPARATION OF APREMILAST AND ITS INTERMEDIATES | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-12-15 | — | — | WO | disclosed |
| WO-2012097116-A2 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | CELGENE CORPORATION (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174627-A1 | Processes For The Preparation Of Beta-Aminosulfone Compounds | TPMT, MPST, CBS | PTGS2 892/4885CALM1 2723/4885SMN1; SMN2 645/4885 |
| US-20200199072-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | TPMT, DHPS, SRMS | PTGS2 287/4885CALM1 2955/4885SMN1; SMN2 804/4885 |
| US-11149003-B2 | Resolution of racemic beta-aminosulfone compounds | TPMT, DHPS, SRMS | PTGS2 287/4885CALM1 2955/4885SMN1; SMN2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.